Merck and Moderna Report Positive Phase 3 Interim Readout for Individualized mRNA Therapy Intismeran in Resected Melanoma

A 1,137-patient trial stopped at its first scheduled look

INTerpath-001 randomized patients with completely resected stage IIB, IIC, III or IV cutaneous melanoma, none of whom had received prior systemic therapy, on a 2:1 basis to intismeran plus Keytruda or to Keytruda alone. The combination arm received 1 mg of intismeran every three weeks for up to nine doses alongside 400 mg of Keytruda every six weeks for up to nine cycles, with treatment running about a year and capped at roughly 56 weeks. The primary endpoint counts any local, locoregional, regional or distant recurrence, or death from any cause, as assessed by the investigator. Distant metastasis-free survival, overall survival, safety, tolerability and quality of life are the key secondary endpoints, and the companies said the study continues under protocol so those can mature. Safety in both arms matched what earlier studies of the combination had shown, with no new signals.

Georgina Long's "landmark moment"

Georgina Long, medical director of Melanoma Institute Australia and chair of melanoma medical oncology and translational research at the University of Sydney, led the trial and supplied the only clinical characterization of the result now in public.

Today's results represent a landmark moment for adjuvant melanoma treatment. This is the first Phase 3 study to show that intismeran, a treatment designed based on the unique mutational 'fingerprint' of a patient's own tumor, given in combination with pembrolizumab can reduce the risk of recurrence or death in patients with completely resected stage IIB-IV melanoma compared to KEYTRUDA alone.

Dean Y. Li, president of Merck Research Laboratories, said the partners will present INTerpath-001 at an international medical meeting and share the findings with regulatory authorities. Neither company has named the meeting or given a submission date. Everything known about the size of the effect comes from a press release and from people who have seen data the rest of the field has not.

Five-year Phase 2b figures set the bar the market is using

The extrapolation runs through KEYNOTE-942, the 157-patient Phase 2b study whose five-year follow-up was presented at the 2026 ASCO annual meeting. There the combination produced a 49% reduction in the risk of recurrence or death, HR 0.51 (95% CI, 0.294 to 0.887), and a 59% reduction in the risk of distant metastasis or death, HR 0.411 (95% CI, 0.200 to 0.843), against Keytruda alone. Moderna management has treated a 20% reduction in the risk of recurrence or death as the program's clinical benchmark, according to analyst notes summarized by BioPharma Dive. Cory Kasimov of Evercore ISI wrote that such a result would be a meaningful step down from previous results, and that a 35% to 40% reduction would read as clearly differentiated.

Every dose begins as a tumor specimen

Intismeran is built per patient. Merck describes the process in a few sentences: the tumor sample is used to identify the mutational signature of that person's cancer, and the resulting therapy is a synthetic mRNA coding for up to 34 neoantigens, translated in the body and presented to the immune system to raise T-cell responses against the tumor. The release gives no manufacturing turnaround time, no failure or dropout rate for specimens that cannot be sequenced, and no account of the workflow between resection and first dose. Daina Graybosch of Leerink Partners wrote that per-patient manufacturing costs for a therapy of this kind are likely higher than for a standard biologic drug, and that assuming success in other tumor types may be a flawed assumption. She also called melanoma "uniquely suited to a vaccine."

Wall Street repriced Moderna by $45 billion

Moderna's share price rose more than 170% on Aug. 19, adding close to $45 billion in market value in a single session and pulling Merck and BioNTech up by double digits, for roughly $92 billion in combined gains, BioPharma Dive reported. Myles Minter of William Blair upgraded Moderna and modeled $5.4 billion in peak annual melanoma sales for the company under its 50-50 revenue split with Merck. Kasimov wrote that the new valuation "already prices in substantially more conviction than the data disclosed thus far supports."

Why This Matters to the APO|APE Reader

Merck and Moderna are running nine Phase 2 and Phase 3 INTerpath trials, with mid-stage kidney and bladder results expected late this year or in 2027 and a late-stage non-small cell lung cancer study underway. An adjuvant regimen keyed to a patient's own mutations makes the resection specimen the starting material for the drug, which draws tissue handling, sequencing quality and turnaround into the treatment pathway in a way an off-the-shelf checkpoint inhibitor never did. None of that pathway has been described publicly, and the medical meeting the companies have promised but not scheduled is where it would first appear.